BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Kremlin: Russian troops conquer Pokrovsk after year of intense combat- Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- Joshua Made Last-Second Seat Change That Saved His Life
- Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors
- 6 Fun Urban areas For Seniors To Travel
- Survey: Protected And Versatile Men's Razor
- Chinese mega embassy could bring security advantages, says No 10
- 10 Asian Countries Perfect for Solo Female Travelers
- Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
